Related
CAMBRIDGE, Ma. (Newsradio 1020 KDKA) - Pittsburgh is one of 87 cities across the country where the next phase of the clinical trials will take place on a promising coronavirus vaccine.
Initial results in humans showed the vaccine, created by Moderna, resulted in antibodies with little to no side effects.
UPMC will take part in conducting phase three trials later this month.
“These positive Phase 1 data are encouraging and represent an important step forward in the clinical development of mRNA-1273, our vaccine candidate against COVID-19, and we thank the NIH for their ongoing collaboration. The Moderna team continues to focus on starting our Phase 3 study this month and, if successful, filing a BLA,” said Stéphane Bancel, Chief Executive Officer of Moderna. “We are committed to advancing the clinical development of mRNA-1273 as quickly and safely as possible while investing to scale up manufacturing so that we can help address this global health emergency.”
If it’s successful, Moderna says they have the capacity to create a billion doses per year. National health officials say it could be ready for distribution early next year.
___Listen to KDKA Radio on the RADIO.COM AppTell your smart speaker to "play News Radio 10 20 KDKA"Receive email updates from KDKA RadioFollow KDKA Radio: Facebook | Twitter | Instagram